SCIENCE FOR BREAKFAST

This is for the early birds that like to have science for breakfast. The breakfast session is the first session of the day, with energising presentations starting at 08:00. A delicious, healthy and fresh breakfast will be served by CRISP (https://www.crisp.nl/)!

Thomas Dierikx (VUmc) will present on ‘’the influence of timing of Maternal administration of Antibiotics during cesarean section on the intestinal Microbial colonization in Infants (the MAMI study)’’ and Marinde van Lennep (AMC) on “Pediatric gastroesophageal reflux disease: developing novel and non-invasive diagnostic tools”.

The Amsterdam Kindersymposium Breakfast Session is powered by

The influence of timing of Maternal administration of Antibiotics during cesarean section on the intestinal Microbial colonization in Infants (the MAMI study.

Thomas Dierikx is a PhD candidate at the department of pediatric gastroenterology of the Amsterdam UMC, location VUmc. His research focuses on pediatric antibiotic exposure and antibiotic induced aberrations of the intestinal microbiota. During the breakfast session he will present the first results of one of his studies entitled: ‘’the influence of timing of Maternal administration of Antibiotics during cesarean section on the intestinal Microbial colonization in Infants (the MAMI study)’’. This study investigates differences in neonatal gut colonization in infants from mothers who received prophylactic antibiotics before caesarean section compared to infants from mothers who received the antibiotics after clamping of the umbilical cord.

Pediatric gastroesophageal reflux disease: developing novel and non-invasive diagnostic tools

Marinde van Lennep works as a PhD candidate at the Emma Children’s hospital / Amsterdam UMC, location AMC, performing research in the field of esophageal motility disorders in children. Her area of interest lies in patients with gastroesophageal reflux disease, esophageal atresia and achalasia. Focus lies on early evaluation and recognition of disordered motility and validation of state-of-the art and exploration of novel techniques that are currently performed in adults. With her work, Marinde aims to provide highly needed evidence based clinical guidelines for these patients to allow patient-tailored screening, diagnostic- and treatment strategies. During the breakfast session she will present the results of her research on pediatric gastroesophageal reflux disease and the development of novel and non-invasive diagnostic tools.

SCIENCE AT LUNCH TIME

Hungry for more science? See you at the Lunch Session! Clara van Karnebeek and Hans Waterham will present on the United for Metabolic Diseases (UMD) consortium for faster diagnosis, improved treatment, and better care and outcome for IEM patients.

 ‘Inborn Errors of Metabolism’ (IEMs) represent a diverse class of >1000 heterogeneous, and often rare genetic diseases. About 1 in 800 newborns is affected with an IEM which, when untreated, may cause early death in some and life-long physical and cognitive complications in many. Given the opportunities for treatment, IEM-patients represent an excellent group for next-generation personalized medicine.

The Amsterdam Kindersymposium Lunch Session is powered by

UMD is a unique collaboration between clinicians, laboratory specialists and researchers from all six Netherlands metabolic academic centers and the patient organization VKS, which fully integrates multiple disciplines, including biomedical research, omics technologies, health care, telemedicine and distant monitoring, education and training, and patient-clinician-research collaborations.

Clara van Karnebeek and Hans Waterham

Focus areas in the UMD are Knowledge Dissemination & Education, to increase awareness and promote early diagnosis and treatment; Technology Innovation, combining and integrating different-omics and big data platforms to improve personalized medicine; Solve the Unsolved, aimed at diagnosis of undiagnosed patients, who have remained undiagnosed, and unraveling underlying disease mechanisms; Innovative treatments and Outcomes, to develop and implement novel treatment options and monitor patients’ outcome.

The synergistic combination, integration and expansion of the clinical, translational and fundamental knowledge and expertise on IEMs existing in the different Netherlands metabolic academic centers, provides a leading international role for the UMD in the development and implementation of improved diagnostics, treatment and care for patients with an IEM.